Biohit Oyj
Stock exchange release
31 January 2012


The Board of Directors of Biohit Oyj has decided at the Board meeting that the company will offer holders of Biohit Oyj convertible bonds to possibility to sell loan back to the company. On 14 December 2011, Biohit Oyj sold its liquid handling business to Sartorius Lab Holding GmbH, and with this sale the financial standing of the company has become significantly stronger.

On 28 October 2010, Biohit Oyj issued a convertible bond targeted at institutional investors. The value at the moment of issue was 4.05 million. The fixed coupon rate of the bond is 6.5% and it has a five-year maturity. Each share of the loan of EUR 4,500 entitles the holder to exchange the share of the loan for 1,000 B shares with a nominal value of EUR 0.17. The rate of exchange of the share is EUR 4.5. The loan can be exchanged for a maximum of 900,000 shares of Biohit Oyj.

Biohit Oyj offers investors in the convertible bond the possibility to sell their loan at its value on 1 February 2012 (the date when the loan will be purchased back). The investors will be paid the nominal capital of the loan and the interest accrued.

For further details, contact:
Semi Korpela
President and CEO
Tel. +358 40 573 7701
semi.korpela@biohit.fi


Distribution:
NASDAQ
OMX Helsinki Oyj
Central Storage Facility (www.oam.fi)
Press
www.biohit.fi

About Biohit
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission crystallizes in its motto "Innovating for Health". The company assumes social responsibility by producing innovations, new technologies and analysis systems for use in medicine, research institutions and industry. These products help to promote research and diagnostics, while improving quality of life by preventing disease, human suffering and financial loss. Biohit also seeks to innovate and develop the marketing and availability of its products and services, in order to ensure its profitable growth and ability to pay dividends.

Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations. These can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. (www.biohit.fi / International / State of the art GastroPanel and Acetium innovations for the unmet need)

Biohit's products include analysis systems for the prevention and early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and H. pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of intestinal bleeding that indicates a risk of colorectal cancer. Acetium reduces the amount of carcinogenic acetaldehyde in an anacidic stomach. (www.acetium.com/test - reveals acetaldehyde exposure)

Biohit employs around 35 people. The company is headquartered in Helsinki, Finland and has a subsidiary in the UK. Since 1999, Biohit's Series B share (BIOBV) has been quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group and is traded under the code BIOBV (www.biohit.fi).

Read more at www.biohit.fi

distribué par

Ce noodl a été diffusé par Biohit Oyj et initialement mise en ligne sur le site http://www.biohit.com. La version originale est disponible ici.

Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-31 18:41:29 PM et restera accessible depuis ce lien permanent.

Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité.